TY  - JOUR
AU  - Vallejo-Vaz, Antonio J
AU  - Bray, Sarah
AU  - Villa, Guillermo
AU  - Brandts, Julia
AU  - Kiru, Gaia
AU  - Murphy, Jennifer
AU  - Banach, Maciej
AU  - De Servi, Stefano
AU  - Gaita, Dan
AU  - Gouni-Berthold, Ioanna
AU  - Kees Hovingh, G
AU  - Jozwiak, Jacek J
AU  - Jukema, J Wouter
AU  - Gabor Kiss, Robert
AU  - Kownator, Serge
AU  - Iversen, Helle K
AU  - Maher, Vincent
AU  - Masana, Luis
AU  - Parkhomenko, Alexander
AU  - Peeters, André
AU  - Clifford, Piers
AU  - Raslova, Katarina
AU  - Siostrzonek, Peter
AU  - Romeo, Stefano
AU  - Tousoulis, Dimitrios
AU  - Vlachopoulos, Charalambos
AU  - Vrablik, Michal
AU  - Catapano, Alberico L
AU  - Poulter, Neil R
AU  - Ray, Kausik K
AU  - DA VINCI Study Investigators
PY  - 2022
DO  - 10.1007/s10557-022-07343-x
UR  - http://hdl.handle.net/10668/20496
T2  - Cardiovascular drugs and therapy
AB  - Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for...
LA  - en
KW  - Atherosclerotic cardiovascular disease
KW  - Cardiovascular disease prevention
KW  - Cardiovascular risk
KW  - LDL-C
KW  - Lipid-lowering
KW  - Statins
TI  - Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
TY  - research article
ER  -